

Quarterly overview

	2021	2020				2019			
	Jan-Mar	Oct-Dec	Jul-Sep	Apr-Jun	Jan-Mar	Oct-Dec	Jul-Sep	Apr-Jun	Jan-Mar
Net sales, SEK million	100.6	92.7	98.8	90.6	118.4	129.3	131.2	119.7	118.6
Gross profit, SEK million	44.7	39.2	45.8	37.0	55.2	57.7	62.3	52.0	54.1
Gross margin, %	44.4	42.3	46.4	40.8	46.6	44.6	47.5	43.4	45.6
EBITDA, SEK million	12.3	3.6	28.9	2.4	20.8	20.3	37.8	11.6	21.7
EBITDA margin, %	12.3	3.9	29.3	2.7	17.5	15.7	28.8	9.7	18.3
Depreciation and impairment of property, plant and equipment, SEK million	4.2	4.2	4.4	4.4	4.5	4.1	4.5	4.7	4.1
EBITA, SEK million	8.1	-0.6	24.5	-1.9	16.2	16.2	33.3	6.9	17.7
EBITA margin, %	8.1	-0.6	24.8	-2.1	13.7	12.5	25.4	5.8	14.9
Amortization and impairment of intangible assets, SEK million ²	1.3	41.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0
EBIT, SEK million	6.8	-41.6	23.5	-3.0	15.2	15.1	32.3	5.9	16.7
EBIT margin, %	6.8	-44.9	23.7	-3.3	12.9	11.7	24.6	5.0	14.1
Profit after tax, SEK million ²	0.3	-32.6	20.2	-43.0	7.4	7.2	20.3	0.3	9.8
Basic earnings per share, SEK	0.02	-1.68	1.04	-2.21	0.38	0.37	1.04	0.01	0.51
Diluted earnings per share, SEK	0.02	-1.68	1.04	-2.21	0.38	0.37	1.04	0.01	0.51
Cash flow from operating activities per share, SEK ¹	0.65	1.30	0.92	0.91	0.75	1.02	1.23	0.80	-0.25
Return on equity, %	0.1	-11.2	6.6	-13.2	2.2	2.2	6.4	0.1	3.2
Net debt/ EBIT (R12)	0.2	0.8	-0.1	0.2	0.0	0.1	0.4	0.7	0.3
Equity/assets ratio, %	54	56	56	53	56	57	56	55	57

¹ IFRS 16 is applied with effect from January 1, 2019, which affects the Group's financial statements, key figures and comparisons between quarters. For more information, see the 2019 Annual Report.

² Profit/loss from biosurfit and the impairment of the Group's holding in the associate in Q2 2020 are not included in the Group's operating profit. The impairment loss of SEK 36.6 million is recognized in net financial income together with biosurfit's profit/loss and is therefore only shown in profit after tax in the quarterly overview.

NEXT 